News
CZ | ENG

 Research of synthetic antibodies iBodies®

Leading scientific institutions have joined forces in researching the synthetic antibodies iBodies®

The Institute of Macromolecular Chemistry of the Czech Academy of Sciences (IMC), in cooperation with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), are moving ahead together in intensive research of synthetic antibody mimetics called iBodies® for their further development. They have just commenced cooperation with the International Cannabis and Cannabinoids Institute (ICCI). In the future, newly prepared iBodies should serve in clinical diagnostics, e.g. histological staining of tissues. The ceremonial signing of the agreement on entering into cooperation took place on Wednesday, October 10 at IMC.

“The need was recognized for right when cooperation started between ICCI with the Masaryk Oncological Institute in Brno and more reliable and more sensitive staining of cannabinoid receptors in tissue samples was needed. During initial tests it was ascertained that commercially available antibodies are not applicable for the staining of cannabinoid receptors on the surface of cancer cells. We therefore turned to two of the leading institutes of the Czech Academy of Sciences, IMC and IOCB Prague, which have presently introduced to the market the first types of iBodies,” explained the reasons for striking up of cooperation Mr. Pavel Kubů, Chief Executive Officer of ICCI.

“Our colleagues from IOCB Prague and ICCI are very important partners to us even beyond the framework of the polymer iBodies project. So I fully embrace this joint project in researching synthetic polymer-based antibody mimetics,” said Mr. Jiří Kotek, Director of the IMC, commenting on the signing of the cooperation agreement. “Now we will jointly work on developing new products on the basis of iBodies. The newly prepared antibody mimetics will be further specifically modified so that it would be possible to use them in diagnostics of cannabinoid receptors in human medicine.

For scientists, iBodies® polymers represent an invaluable tool because they make it possible to visualize a specific protein on the surface of cells, or isolate these proteins from the blood and other tissues. In the future, these polymer conjugates could significantly increase the effectiveness and improve an entire series of applied biochemical methods in research as well as in clinical practice. “Intuition tells me that iBodies have great potential, and that we will ultimately not be sticking with only synthetic antibody mimetics, but more of their unique and yet unseen advantages will reveal themselves. So it is up to every specific project and targeted application so that the potential of these original molecules could fully appear. That is one more reason I’m so happy with the prospects of this new project with our colleagues from IMC and ICCI, with whom we will keep developing iBodies,“ added the director of IOCB Prague, Mr. Zdeněk Hostomský regarding their cooperation.

The aim of developing iBodies® is to replace expensive and not always available specific antibodies that are necessary for most biochemical methods. As opposed to antibodies themselves, iBodies® are water-soluble polymer conjugates decorated with small organic molecules, usually enzyme inhibitors or receptor ligands. These crucial components are responsible for selective binding of iBodies® to target enzymes/receptors on a cell surface. Recent lab test results have shown that the prepared iBodies® are at the very least comparable with commercially available antibodies, and have demonstrated even better sensitivity and stability in several biochemical methods.

The designation iBody comes from the combination of two words: inhibitor and antibody. The term refers to the function of iBodies as antibody mimetics. Besides attached inhibitors, iBodies also contain “anchor” molecules (enabling immobilization of iBodies to a solid phase during separation techniques), and reporters, mostly fluorescent molecules (enabling easy visualization of iBodies® by various laboratory techniques).

Learn more on the technology iBodies® at the website  www.ibodies.eu.

Agreement signing

 

 

Media contact:

RNDr. Tomáš Etrych, PhD, DSc
Head of the Biomedical Polymers Department at the Institute of Macromolecular Chemistry of the CAS 
+420 737 304 415

www.imc.cas.cz

 

Dušan Brinzanik

Institute of Organic Chemistry and Biochemistry of the CAS – Communication

+420 731 609 271

www.uochb.cz         

 

Jakub Večerka

International Cannabis and Cannabinoids Institute s.r.o. - PR manager

+420 603 185 441

jakub.vecerka@icci.science

Agreement signing 2
 

The Institute of Macromolecular Chemistry of the Czech Academy of Sciences (IMC) is the Czech Republic's largest and a globally respected institution, which has concentrated important researchers in the area of macromolecular science, with the aim of preparing new polymer materials and discovering relationships and regularities between their molecular structure and the resulting properties.

 

Polymer materials have now become an integral part of modern human civilization, and are all around us. Today however, the role of polymers is gradually changing, and macromolecular materials are in increasing measure becoming special construction materials of unforeseen optoelectronic and mechanical properties. Right from the establishment of this institute by Professor O. Wichterle in 1959, polymers were counted on to become materials that could correct deficiencies of the human body. This led to the birth of the contact lens. Currently polymer configurations are used as carriers of therapeutic or diagnostic materials, they support the growth of damaged tissues, and in combination with nano-particles, they react to external stimuli and are becoming “intelligent” materials. It is now the 21st century, which is prepared to use the potential of these materials, and just like in the previous century, the IMC not only monitors but even sets the trend of modern macromolecular science, all to bring to life new, unique and mainly useful materials.

 

 

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading internationally recognized scientific institution whose primary mission is the pursuit of basic research in chemical biology and medicinal chemistry, organic and materials chemistry, chemistry of natural substances, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. An integral part of the IOCB Prague’s mission is the implementation of the results of basic research in practice. Emphasis on interdisciplinary research gives rise to a wide range of applications in medicine, pharmacy, and other fields. This is the concern of the institute's subsidiaries - the companies IOCB Tech (formerly IOCB TTO) and i&i Prague.

 

 

The International Cannabis and Cannabinoids Institute ICCI (International Cannabis and Cannabinoids Institute) was established as a common project of patient organizations, Czech scientific societies and the American investment firm Dioscorides Global Holdings. It is headquartered in Prague, and as a so-called center of excellence, it cooperates for example with Charles University, Czech Technical University, the Czech University of Life Sciences in Prague, Masaryk University in Brno, Mendel University in Brno, Palacký University in Olomouc, and Hebrew University in Jerusalem.

All articles

Otto Wichterle Centre of Polymer Materials and Technologies - CPMTOW

Centre of Biomedicinal Polymers - CBMP

Centre of Polymer Sensors - CPS

Polymers for Power Engineering - Energolab


 

Institute of Macromolecular Chemistry AS CR
Heyrovského nám. 2
162 06 Prague 6
Czech Republic
tel:+420 296 809 111
fax:+420 296 809 410

Strategie 21

Molekuly a materiály pro život